RxDoctor Payments Data

Leo Teytelbaum, MD

Internal Medicine · St Petersburg, FLNPI 1053388512

Payments from drug & device makers

$3,587in general payments, 2019–2025

Across 167 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$536
  • Mylan Specialty L.p.$489
  • Sanofi-aventis U.S. LLC$351
  • Pfizer$303
  • Amarin Pharma, Inc.$272
  • Boehringer Ingelheim$218
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,56399%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,587 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$273,396
Medicare patients
140
Services billed
2,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$75,782
OzempicSemaglutide23$23,728
OxycontinOxycodone Hcl13$22,877
Janumet XrSitagliptin Phos/Metformin Hcl15$19,520
Trijardy XrEmpaglifloz/Linaglip/Metformin16$17,648
TrulicityDulaglutide13$15,750
Risperdal ConstaRisperidone Microspheres14$14,913
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,991
MounjaroTirzepatide13$12,954
MyrbetriqMirabegron22$12,034
TradjentaLinagliptin22$11,140
Potassium Chloride74$8,529
RestasisCyclosporine19$6,656
FarxigaDapagliflozin Propanediol11$6,460
Breo ElliptaFluticasone/Vilanterol12$4,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$303$75,78283 claims
Boehringer IngelheimTrijardy Xr, Tradjenta$218$28,78838 claims
Lilly USA, LLCTrulicity, Mounjaro$152$28,70326 claims
Novo NordiskOzempic$213$23,72823 claims
MerckJanumet Xr$31$19,52015 claims
GSKTrelegy Ellipta, Breo Ellipta$86$17,80024 claims
Johnson & JohnsonRisperdal Consta$536$14,91314 claims
AbbVieRestasis, Synthroid$93$7,62430 claims
AstraZenecaFarxiga$119$6,46011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →